These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 16184712)

  • 1. PET-scan in colorectal cancer.
    Lonneux M
    Acta Chir Belg; 2005 Aug; 105(4):333-7. PubMed ID: 16184712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
    Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
    Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence.
    Deleau C; Buecher B; Rousseau C; Kraeber-Bodéré F; Flamant M; des Varannes SB; Frampas E; Galmiche JP; Matysiak-Budnik T
    Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):275-81. PubMed ID: 21304319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positron emission tomography in colorectal cancer.
    Flamen P
    Best Pract Res Clin Gastroenterol; 2002 Apr; 16(2):237-51. PubMed ID: 11969236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer.
    Laurens ST; Oyen WJ
    PET Clin; 2015 Jul; 10(3):345-60. PubMed ID: 26099671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing the role of FDG PET-CT for potentially operable metastatic colorectal cancer.
    Culverwell AD; Chowdhury FU; Scarsbrook AF
    Abdom Imaging; 2012 Dec; 37(6):1021-31. PubMed ID: 22371087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [18F-fluorodeoxyglucose positron emission tomography in colorectal cancer: value in primary staging and follow-up].
    Jörg L; Heinisch M; Rechberger E; Kurz F; Klug R; Aufschnaiter M; Hammer J; Langsteger W
    Acta Med Austriaca; 2002; 29(5):176-9. PubMed ID: 12506769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Established, emerging and future roles of PET/CT in the management of colorectal cancer.
    Herbertson RA; Scarsbrook AF; Lee ST; Tebbutt N; Scott AM
    Clin Radiol; 2009 Mar; 64(3):225-37. PubMed ID: 19185652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer.
    Pelosi E; Deandreis D
    Eur J Surg Oncol; 2007 Feb; 33(1):1-6. PubMed ID: 17126522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomography scanning is not superior to whole body multidetector helical computed tomography in the preoperative staging of colorectal cancer.
    Furukawa H; Ikuma H; Seki A; Yokoe K; Yuen S; Aramaki T; Yamagushi S
    Gut; 2006 Jul; 55(7):1007-11. PubMed ID: 16361308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [18F]Fluorodeoxyglucose PET/Computed Tomography in Gastrointestinal Malignancies.
    Donswijk ML; Hess S; Mulders T; Lam MG
    PET Clin; 2014 Oct; 9(4):421-41, v-vi. PubMed ID: 26050945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Importance of FDG-PET/computed tomography in colorectal cancer].
    Kleiner S; Weber W
    Radiologe; 2019 Sep; 59(9):812-819. PubMed ID: 31428810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can (18)F-FDG PET/CT scan change treatment planning and be prognostic in recurrent colorectal carcinoma? A prospective and follow-up study.
    Artiko V; Odalovic S; Sobic-Saranovic D; Petrovic M; Stojiljkovic M; Petrovic N; Kozarevic N; Grozdic-Milojevic I; Obradovic V
    Hell J Nucl Med; 2015; 18(1):35-41. PubMed ID: 25840571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of FDG-PET staging in selecting the optimum patient for hepatic resection of metastatic colorectal cancer.
    Strasberg SM; Dehdashti F
    J Surg Oncol; 2010 Dec; 102(8):955-9. PubMed ID: 21165998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical use of 18F-FDG PET/CT in colorectal carcinoma].
    Németh Z; Boér K; Kásler M; Borbély K
    Orv Hetil; 2013 Sep; 154(37):1447-53. PubMed ID: 24016751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between serum CEA level and metabolic volume as determined by FDG PET in postoperative patients with recurrent colorectal cancer.
    Choi MY; Lee KM; Chung JK; Lee DS; Jeong JM; Park JG; Kim JH; Lee MC
    Ann Nucl Med; 2005 Apr; 19(2):123-9. PubMed ID: 15909492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG PET and PET/CT for colorectal cancer.
    Delbeke D; Martin WH
    Methods Mol Biol; 2011; 727():77-103. PubMed ID: 21331930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of laxative-augmented contrast medium in the evaluation of colorectal foci at FDG PET.
    Chen YK; Chen JH; Tsui CC; Chou HH; Cheng RH; Chiu JS
    Radiology; 2011 May; 259(2):525-33. PubMed ID: 21406631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fluorine-18-2-deoxy-2-fluoro-D-glucose positron emission tomography in colorectal cancer].
    Tang G; Kuang A
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2005 Feb; 22(1):193-6, 201. PubMed ID: 15762148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer.
    Lonneux M; Reffad AM; Detry R; Kartheuser A; Gigot JF; Pauwels S
    Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):915-21. PubMed ID: 12111132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.